Related Experiment Video
Updated: Apr 20, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
Topoisomerase 1 inhibition reversibly impairs synaptic function
Angela M Mabb1, Paul H M Kullmann1, Margaret A Twomey1
1Department of Cell Biology and Physiology, University of North Carolina Neuroscience Center, Carolina Institute for Developmental Disabilities, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
Abstract:
Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABA(A)β3. Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.
Insights
Topoisomerase 1 (TOP1) inhibition by topotecan reduces synaptic proteins and impairs neuronal network activity. These effects on synapse function and protein levels are reversible, suggesting TOP1
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Topotecan is a topoisomerase 1 (TOP1) inhibitor used in cancer therapy.
- Previous research indicated topotecan reduces expression of long genes, including neuronal genes associated with synapses and autism.
- The impact of topotecan on synaptic protein levels and synapse function remained uninvestigated.
Purpose of the Study:
- To investigate the effects of topotecan on synaptic protein levels in primary cortical neurons.
- To determine whether topotecan alters synaptic function, including excitatory and inhibitory neurotransmission.
- To assess the reversibility of topotecan-induced changes in synaptic protein levels and function.
Main Methods:
- Treatment of primary cortical neurons with topotecan.
- Measurement of synaptic protein levels (Neurexin-1, Neuroligin-1, Cntnap2, GABA(A)β3).
- Electrophysiological recordings to assess spontaneous network activity, resting membrane potential, action potential threshold, and neurotransmission.
- Evaluation of reversibility upon drug washout.
Main Results:
- Topotecan depleted synaptic proteins encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABA(A)β3.
- Topotecan suppressed spontaneous network activity without affecting neuron health or basic electrophysiological properties.
- Both inhibitory and excitatory neurotransmission were significantly reduced by topotecan.
- The observed effects on synaptic proteins and inhibitory neurotransmission were fully reversible after drug removal.
Conclusions:
- Topoisomerase 1 (TOP1) plays a critical role in regulating the expression of multiple synaptic proteins.
- TOP1 activity is essential for normal excitatory and inhibitory synaptic transmission.
- Topotecan's impact on synaptic function is reversible, suggesting potential therapeutic implications.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting Neurotransmitter Release or Uptake
Excitatory and Inhibitory Effects of Neurotransmitters
Drugs that Destabilize Microtubules
Neurochemical Transmission: Sites of Drug Action

